129 related articles for article (PubMed ID: 1384958)
21. Induction of cytotoxic T lymphocytes following immunization with cationized soluble antigen.
Ikenaga T; Yamasaki Y; Shakushiro K; Nishikawa M; Takakura Y
Vaccine; 2004 Jun; 22(20):2609-16. PubMed ID: 15193386
[TBL] [Abstract][Full Text] [Related]
22. Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells.
Ke Y; Kapp JA
J Immunol; 1996 Feb; 156(3):916-21. PubMed ID: 8558017
[TBL] [Abstract][Full Text] [Related]
23. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling.
Met O; Wang M; Pedersen AE; Nissen MH; Buus S; Claesson MH
Cancer Lett; 2006 Jan; 231(2):247-56. PubMed ID: 16399226
[TBL] [Abstract][Full Text] [Related]
24. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
[TBL] [Abstract][Full Text] [Related]
25. Injection site-dependent induction of immune response by DNA vaccine: comparison of skin and spleen as a target for vaccination.
Guan X; Nishikawa M; Takemoto S; Ohno Y; Yata T; Takakura Y
J Gene Med; 2010 Mar; 12(3):301-9. PubMed ID: 20084616
[TBL] [Abstract][Full Text] [Related]
26. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
Hao S; Bai O; Yuan J; Qureshi M; Xiang J
Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
[TBL] [Abstract][Full Text] [Related]
27. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
[TBL] [Abstract][Full Text] [Related]
28. Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor.
Makki A; Weidt G; Blachere NE; Lefrançois L; Srivastava PK
Cancer Immun; 2002 Apr; 2():4. PubMed ID: 12747749
[TBL] [Abstract][Full Text] [Related]
29. Induction of antigen-specific cytotoxic T lymphocytes by immunization with negatively charged soluble antigen through scavenger receptor-mediated delivery.
Yamasaki Y; Ikenaga T; Otsuki T; Nishikawa M; Takakura Y
Vaccine; 2007 Jan; 25(1):85-91. PubMed ID: 16956699
[TBL] [Abstract][Full Text] [Related]
30. Costimulation provided by DNA immunization enhances antitumor immunity.
Corr M; Tighe H; Lee D; Dudler J; Trieu M; Brinson DC; Carson DA
J Immunol; 1997 Nov; 159(10):4999-5004. PubMed ID: 9366427
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice.
Hattori Y; Kawakami S; Suzuki S; Yamashita F; Hashida M
Biochem Biophys Res Commun; 2004 May; 317(4):992-9. PubMed ID: 15094367
[TBL] [Abstract][Full Text] [Related]
32. [Enhanced translational efficacy of internal ribosomal entry site-mediated mRNA in dendritic cells contributes to efficient induction of antitumor immunity].
Tan XH; Wan YH
Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(6):399-403. PubMed ID: 17456382
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
Maecker HT; Umetsu DT; DeKruyff RH; Levy S
J Immunol; 1998 Dec; 161(12):6532-6. PubMed ID: 9862678
[TBL] [Abstract][Full Text] [Related]
34. Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo.
Ishioka GY; Colon S; Miles C; Grey HM; Chesnut RW
J Immunol; 1989 Aug; 143(4):1094-100. PubMed ID: 2787356
[TBL] [Abstract][Full Text] [Related]
35. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.
Porgador A; Staats HF; Faiola B; Gilboa E; Palker TJ
J Immunol; 1997 Jan; 158(2):834-41. PubMed ID: 8993001
[TBL] [Abstract][Full Text] [Related]
36. Enhanced antigen-specific antibody production following polyplex-based DNA vaccination via the intradermal route in mice.
Kawase A; Isaji K; Yamaoka A; Kobayashi N; Nishikawa M; Takakura Y
Vaccine; 2006 Jul; 24(27-28):5535-45. PubMed ID: 16716462
[TBL] [Abstract][Full Text] [Related]
37. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
[TBL] [Abstract][Full Text] [Related]
38. Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell responses.
Xie Y; Bai O; Yuan J; Chibbar R; Slattery K; Wei Y; Deng Y; Xiang J
Cancer Res; 2009 Oct; 69(19):7756-66. PubMed ID: 19789353
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cells that endocytosed antigen-containing IgG-liposomes elicit effective antitumor immunity.
Kawamura K; Kadowaki N; Suzuki R; Udagawa S; Kasaoka S; Utoguchi N; Kitawaki T; Sugimoto N; Okada N; Maruyama K; Uchiyama T
J Immunother; 2006; 29(2):165-74. PubMed ID: 16531817
[TBL] [Abstract][Full Text] [Related]
40. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.
Gavioli R; Cellini S; Castaldello A; Voltan R; Gallerani E; Gagliardoni F; Fortini C; Cofano EB; Triulzi C; Cafaro A; Srivastava I; Barnett S; Caputo A; Ensoli B
Vaccine; 2008 Jan; 26(5):727-37. PubMed ID: 18096278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]